STOCK TITAN
  1. Home
  2. News
  3. WVE

Wave Life Sciences Ltd. - WVE STOCK NEWS

Welcome to our dedicated news page for Wave Life Sciences Ltd. (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Sciences Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wave Life Sciences Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wave Life Sciences Ltd.'s position in the market.

News
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Rhea-AI Summary
Wave Life Sciences announces continued momentum in GSK collaboration with the selection of two programs for development, initiation of clinical trials for the INHBE program in obesity, and upcoming presentations at key conferences. GSK collaboration progresses with an aggregate initiation payment of $12 million for two oligonucleotide programs using Wave's next generation GalNAc-siRNA format. Wave expects up to $3.3 billion in potential milestone payments and tiered royalties on net sales from the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none
-
News
Wave Life Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Wave Life Sciences (WVE) announced that their CEO will participate in two investor conferences in April. The company aims to leverage RNA medicines for health benefits. Webcasts of the events will be available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.71%
Tags
conferences
-
News
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Wave Life Sciences (WVE) announces lead clinical candidate selection for potential best-in-class obesity treatment with promising clinical trial updates. Financially, the company reports strong cash position and revenue growth, with positive outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.32%
Tags
earnings
News
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
Rhea-AI Summary
Wave Life Sciences Ltd. will host a live webcast and conference call to discuss its fourth quarter and full year 2023 financial results and business updates on March 6, 2024. The event aims to provide insights into the company's performance and future prospects in the RNA medicines sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
Rhea-AI Summary
Wave Life Sciences presents promising data on WVE-N531 for Duchenne muscular dystrophy at the 2024 MDA Conference, showcasing potential therapeutic effects on satellite cells and muscle regeneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
conferences
-
News
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) announced key 2024 milestones across its clinical programs, growing pipeline, and leading RNA medicines platform. The company is well-capitalized with $142 million of cash inflows in 4Q 2023, including $115 million from December financing and $27 million in collaboration milestone payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
none
News
Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Paul Bolno, MD, MBA, President and CEO, to speak on January 10, 2024, at 3:00 p.m. PT / 6:00 p.m. ET. A live webcast will be available on the Investor Relations page of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
conferences
-
News
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) has initiated dosing in the Phase 2 FORWARD-53 clinical trial, evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. The trial aims to assess functional dystrophin protein at 24 and 48 weeks with every other week dosing of WVE-N531. The company has demonstrated the highest level of exon skipping ever observed in the clinic and high muscle concentrations of WVE-N531 in skeletal muscle of 6.1 micromolar. The potential for monthly dosing in the future is also anticipated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
clinical trial
-
News
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) announced the pricing of its underwritten public offering of 20,000,000 ordinary shares at $5.00 per share, expecting to raise approximately $100 million. The company granted underwriters a 30-day option to purchase up to an additional 3,000,000 shares. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.42%
Tags
offering
News
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Rhea-AI Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and pre-funded warrants to purchase ordinary shares. The offering is subject to market and other conditions, with J.P. Morgan and Leerink Partners acting as joint book-running managers. The company intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and pre-funded warrants sold in the public offering on the same terms and conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.42%
Tags
offering
Stock WVE logo
Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#2849 Ranked by Market Cap
#1217 Ranked by Stock Gains
N/A Ranked by Dividends

WVE Stock Data

709.25M
67.25M
18.2%
74.85%
2.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Singapore
7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.